Nuvation Bio Inc. (NUVB)

NYSE: NUVB · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2020

Full chart Alerts Compare

Grade5.4

◀ Past 6.2● Present 4.6▶ Future 5.8

2 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The grade of Nuvation Bio Inc.

Nine metrics read from its own filings, by tense

Headline grade

5.4/10

◀ Past6.230% of the headline

● Present4.640% of the headline

▶ Future5.830% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

6.2/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed

2.8/10

Has it survived what it has been through?

3 warning events since 2020; the latest 2021-05-14.

weight 33% of this tense · 27th percentile among 497 sector filers · read for itself

From the record

Nuvation Bio Inc.'s filings since 2020 show 3 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2021-02-12); a warning not to rely on past financial statements (8-K item 4.02, the latest 2021-05-14); an auditor change (8-K item 4.01, the latest 2021-02-12) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed

9.1/10

What has it actually done, year after year?

3 filed years; profit years unseen.

weight 45% of this tense · 91st percentile among 323 sector filers · read for its customers

From the record

Nuvation Bio Inc.'s 3 filed years say what it did: it rose in 1 of 1 years; it never fell from a peak (its annual reports).

What it rests on

the share of years revenue rosetop 8% of its family
the deepest fall from a revenue peak0.0%top 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate

5.5/10

How has it treated the people who own it?

SI estimate 5.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 55th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: Read from one part only, the share count over the years, which ranks in the top 45% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read: Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned: one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence: 35 of 100
What would change it: A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Nuvation Bio Inc.'s shareholder treatment is put at 5.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 45% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.6/1040% of the headline grade · 3 of 3 filed

Financial health

as filed

4.0/10

Is it financially healthy right now?

ROE -67%: lost 67¢ per shareholder dollar. Leverage 49%: owes 49¢ per asset dollar.

weight 45% of this tense · 40th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Nuvation Bio Inc. lost about 67 cents for every dollar of shareholders' money. Leverage: it owed about 49 cents per dollar of assets, and net share issuance: its share count grew 27.1% over the year (the filed statements).

What it rests on

what it owes per dollar of assetsbottom 35% of its family
return on equitybottom 42% of its family
the share count against the year beforebottom 44% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed

5.0/10

How strong is its position in its industry?

top 50% of 315 in its family; net margin -325.3%.

weight 33% of this tense · 50th percentile among 315 sector filers · read for its customers

From the record

Nuvation Bio Inc.'s standing among 315 graded names in its industry family: revenue of $63 million in fiscal 2025 ranks in the top 41% by size; a net margin of -325.3% ranks in the bottom 41% (its annual reports).

What it rests on

revenue against the family$62.9Mtop 41% of its family
net margin-325.3%bottom 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed

5.0/10

What are the people in charge doing?

top 50% of 315 in its family for leadership; chief executive since 2021.

weight 22% of this tense · 50th percentile among 315 sector filers · read for its shareholders

From the record

Nuvation Bio Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hung, David (PRESIDENT AND CEO, as filed), filing under that title since 2021-02-12, 5.7 years (top 43% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.4 years (bottom 45%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

officer and director changes on Form 8-K, against the people in charge7 in three years among 15 peoplebottom 49% of its family
the median years the people in charge have filed5.4 yearsbottom 45% of its family
the chief executive's years on the record5.7 yearstop 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

5.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

as filed

4.6/10

How much room does it have to grow?

bottom 46% of 273 in its family for room to expand.

weight 45% of this tense · 46th percentile among 273 sector filers · read for itself

From the record

Nuvation Bio Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $164 million against debt of $47 million leaves 19.6% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is -275.7% of revenue (bottom 41%); research spending of 183% of revenue (top 43%) (its annual report).

What it rests on

cash less debt against assets19.6%bottom 39% of its family
cash from operations less capital spending against revenue-275.7%bottom 41% of its family
research spending against revenue183.0%top 43% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed

7.8/10

What could actually drive growth from here?

top 22% of 306 in its family for growth drivers.

weight 33% of this tense · 78th percentile among 306 sector filers · read for its customers

From the record

Nuvation Bio Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 700.1% (top 5%); research spending grew 9.4% a year (top 39%) (its annual reports). Nuvation Bio Inc. reported 2 product lines in fiscal 2025: License at $38 million (61%), Product at $25 million (39%); 1 of 1 grew against the year before (its annual report).

What it rests on

the newest year's revenue growth700.1%top 5% of its family
three-year growth of research spending9.4%top 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

SI estimate

5.3/10

Did its newest year beat what its own record pointed to?

SI estimate 5.3/10, confidence 20 of 100 (family median).

weight 22% of this tense · 50th percentile among 234 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one.
What the record cannot read: The record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change.
How it was reasoned: family median, 234 readings behind it.
Confidence: 20 of 100
What would change it: Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Nuvation Bio Inc.'s expectations vs reality is put at 5.3 of 10 with a confidence of 20 of 100, because the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change, so the desk assumes the typical reading of its industry family, the median of 234 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NUVB · research, not advice